HER2 overexpression occurs in 2–38% of adenocarcinomas and in 1–16% of squamous carcinomas, while HER2 mutations appear in 2% of cases, with exon 20 in-frame insertion being the most frequent type predominantly found among non-smoker females [87,88]. Here, ERBB2 is linked to squamous cell carcinoma.